Impacts of the Tropical Pacific/Indian Oceans on the Seasonal Cycle of the West African Monsoon

The current consensus is that drought has developed in the Sahel during the second half of the twentieth century as a result of remote effects of oceanic anomalies amplified by local land–atmosphere interactions. This paper focuses on the impacts of oceanic anomalies upon West African climate and specifically aims to identify those from SST anomalies in the Pacific/Indian Oceans during spring and summer seasons, when they were significant. Idealized sensitivity experiments are performed with four atmospheric general circulation models (AGCMs). The prescribed SST patterns used in the AGCMs are based on the leading mode of covariability between SST anomalies over the Pacific/Indian Oceans and summer rainfall over West Africa. The results show that such oceanic anomalies in the Pacific/Indian Ocean lead to a northward shift of an anomalous dry belt from the Gulf of Guinea to the Sahel as the season advances. In the Sahel, the magnitude of rainfall anomalies is comparable to that obtained by other authors using SST anomalies confined to the proximity of the Atlantic Ocean. The mechanism connecting the Pacific/Indian SST anomalies with West African rainfall has a strong seasonal cycle. In spring (May and June), anomalous subsidence develops over both the Maritime Continent and the equatorial Atlantic in response to the enhanced equatorial heating. Precipitation increases over continental West Africa in association with stronger zonal convergence of moisture. In addition, precipitation decreases over the Gulf of Guinea. During the monsoon peak (July and August), the SST anomalies move westward over the equatorial Pacific and the two regions where subsidence occurred earlier in the seasons merge over West Africa. The monsoon weakens and rainfall decreases over the Sahel, especially in August.Peer reviewe

Severe early onset preeclampsia: short and long term clinical, psychosocial and biochemical aspects

Preeclampsia is a pregnancy specific disorder commonly defined as de novo hypertension and proteinuria after 20 weeks gestational age. It occurs in approximately 3-5% of pregnancies and it is still a major cause of both foetal and maternal morbidity and mortality worldwide1. As extensive research has not yet elucidated the aetiology of preeclampsia, there are no rational preventive or therapeutic interventions available. The only rational treatment is delivery, which benefits the mother but is not in the interest of the foetus, if remote from term. Early onset preeclampsia (<32 weeks’ gestational age) occurs in less than 1% of pregnancies. It is, however often associated with maternal morbidity as the risk of progression to severe maternal disease is inversely related with gestational age at onset2. Resulting prematurity is therefore the main cause of neonatal mortality and morbidity in patients with severe preeclampsia3. Although the discussion is ongoing, perinatal survival is suggested to be increased in patients with preterm preeclampsia by expectant, non-interventional management. This temporising treatment option to lengthen pregnancy includes the use of antihypertensive medication to control hypertension, magnesium sulphate to prevent eclampsia and corticosteroids to enhance foetal lung maturity4. With optimal maternal haemodynamic status and reassuring foetal condition this results on average in an extension of 2 weeks. Prolongation of these pregnancies is a great challenge for clinicians to balance between potential maternal risks on one the eve hand and possible foetal benefits on the other. Clinical controversies regarding prolongation of preterm preeclamptic pregnancies still exist – also taking into account that preeclampsia is the leading cause of maternal mortality in the Netherlands5 - a debate which is even more pronounced in very preterm pregnancies with questionable foetal viability6-9. Do maternal risks of prolongation of these very early pregnancies outweigh the chances of neonatal survival? Counselling of women with very early onset preeclampsia not only comprises of knowledge of the outcome of those particular pregnancies, but also knowledge of outcomes of future pregnancies of these women is of major clinical importance. This thesis opens with a review of the literature on identifiable risk factors of preeclampsia

Penilaian Kinerja Keuangan Koperasi di Kabupaten Pelalawan

This paper describe development and financial performance of cooperative in District Pelalawan among 2007 - 2008. Studies on primary and secondary cooperative in 12 sub-districts. Method in this stady use performance measuring of productivity, efficiency, growth, liquidity, and solvability of cooperative. Productivity of cooperative in Pelalawan was highly but efficiency still low. Profit and income were highly, even liquidity of cooperative very high, and solvability was good

Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19

: Pediatric Coronavirus Disease 2019 (pCOVID-19) is rarely severe; however, a minority of children infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might develop multisystem inflammatory syndrome in children (MIS-C), with substantial morbidity. In this longitudinal multi-institutional study, we applied multi-omics (analysis of soluble biomarkers, proteomics, single-cell gene expression and immune repertoire analysis) to profile children with COVID-19 (n = 110) and MIS-C (n = 76), along with pediatric healthy controls (pHCs; n = 76). pCOVID-19 was characterized by robust type I interferon (IFN) responses, whereas prominent type II IFN-dependent and NF-κB-dependent signatures, matrisome activation and increased levels of circulating spike protein were detected in MIS-C, with no correlation with SARS-CoV-2 PCR status around the time of admission. Transient expansion of TRBV11-2 T cell clonotypes in MIS-C was associated with signatures of inflammation and T cell activation. The association of MIS-C with the combination of HLA A*02, B*35 and C*04 alleles suggests genetic susceptibility. MIS-C B cells showed higher mutation load than pCOVID-19 and pHC. These results identify distinct immunopathological signatures in pCOVID-19 and MIS-C that might help better define the pathophysiology of these disorders and guide therapy

Atención al paciente oncológico en tiempos de COVID-19

Introduction: with the emergence of the new coronavirus and the wide worldwide distribution, its effects in people with some comorbidities are a global concern. Cancer is a disease with a high incidence and prevalence in society, included among the main causes of mortality.Objective: to describe the management of cancer patients during COVID-19Method: a literature review of articles published up to June 2020 was carried out, using the Pubmed / Medline, SCOPUS and SciELO databases. 28 references were selected for the preparation of the present.Development: cancer has variable clinical and prognostic behaviors that generally lead to states of immunosuppression caused by the therapeutics used for its treatment; Therefore, they are more vulnerable to infectious diseases. The proper care of this group of people is the responsibility of the health systems. Some measures are based on social distancing, either in reducing the number of companions of the patient in the consultation or chemotherapy sessions, the prohibition of visits to hospitalized patients and the use of technologies with the use of teleconsultations for routine follow-up, as well as the change from intravenous to oral treatmentsConclusions: the study of the behavior of COVID-19 in cancer patients is under development. The measures that the institutions take to achieve quality care for people with cancer are varied and are based mainly on social distancing.Introducción: con el surgimiento del nuevo coronavirus y la amplia distribución mundial, es una preocupación global sus efectos en personas con algunas comorbilidades. El cáncer es una enfermedad con alta incidencia y prevalencia en la sociedad, incluida entre las principales causas de mortalidad.Objetivo: describir el manejo del paciente oncológico durante la COVID-19Método: se realizó una revisión de la literatura de artículos publicados hasta junio del 2020, utilizando las bases de datos de Pubmed/Medline, SCOPUS y SciELO. Se seleccionaron 28 referencias para la elaboración de la presente.Desarrollo: el cáncer posee comportamientos clínicos y pronóstico variables que generalmente conllevan a estados de inmunosupresión causada por la terapéutica empleada para su tratamiento; por lo cual presentan mayor vulnerabilidad ante enfermedades infecciosas. Es responsabilidad de los sistemas de salud la correcta atención a este grupo de personas. Algunas medidas se basan en el distanciamiento social, ya sea en la reducción de la cantidad de acompañantes del paciente en la consulta o las sesiones de quimioterapia, la prohibición de las visitas a los pacientes hospitalizados y el empleo de las tecnologías con el uso de las teleconsultas para el seguimiento rutinario, así como el cambio de tratamientos por vía intravenosa a vía oralConclusiones: el estudio del comportamiento de la COVID-19 en pacientes oncológicos está en desarrollo. Las medidas que tomen las instituciones para lograr una atención de calidad a las personas que poseen cáncer son variadas y se basan sobre todo en el distanciamiento social

Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

Publisher Copyright: © 2021 The Authors, some rights reserved.Circulating autoantibodies (auto-Abs) neutralizing high concentrations (10 ng/ml; in plasma diluted 1:10) of IFN-alpha and/or IFN-omega are found in about 10% of patients with critical COVID-19 (coronavirus disease 2019) pneumonia but not in individuals with asymptomatic infections. We detect auto-Abs neutralizing 100-fold lower, more physiological, concentrations of IFN-alpha and/or IFN-omega (100 pg/ml; in 1:10 dilutions of plasma) in 13.6% of 3595 patients with critical COVID-19, including 21% of 374 patients >80 years, and 6.5% of 522 patients with severe COVID-19. These antibodies are also detected in 18% of the 1124 deceased patients (aged 20 days to 99 years; mean: 70 years). Moreover, another 1.3% of patients with critical COVID-19 and 0.9% of the deceased patients have auto-Abs neutralizing high concentrations of IFN-beta. We also show, in a sample of 34,159 uninfected individuals from the general population, that auto-Abs neutralizing high concentrations of IFN-alpha and/or IFN-omega are present in 0.18% of individuals between 18 and 69 years, 1.1% between 70 and 79 years, and 3.4% >80 years. Moreover, the proportion of individuals carrying auto-Abs neutralizing lower concentrations is greater in a subsample of 10,778 uninfected individuals: 1% of individuals 80 years. By contrast, auto-Abs neutralizing IFN-beta do not become more frequent with age. Auto-Abs neutralizing type I IFNs predate SARS-CoV-2 infection and sharply increase in prevalence after the age of 70 years. They account for about 20% of both critical COVID-19 cases in the over 80s and total fatal COVID-19 cases.Peer reviewe

Pregnancy-related pelvic girdle pain: an update

A large number of scientists from a wide range of medical and surgical disciplines have reported on the existence and characteristics of the clinical syndrome of pelvic girdle pain during or after pregnancy. This syndrome refers to a musculoskeletal type of persistent pain localised at the anterior and/or posterior aspect of the pelvic ring. The pain may radiate across the hip joint and the thigh bones. The symptoms may begin either during the first trimester of pregnancy, at labour or even during the postpartum period. The physiological processes characterising this clinical entity remain obscure. In this review, the definition and epidemiology, as well as a proposed diagnostic algorithm and treatment options, are presented. Ongoing research is desirable to establish clear management strategies that are based on the pathophysiologic mechanisms responsible for the escalation of the syndrome's symptoms to a fraction of the population of pregnant women

Age and frailty are independently associated with increased COVID-19 mortality and increased care needs in survivors: results of an international multi-centre study

INTRODUCTION: Increased mortality has been demonstrated in older adults with COVID-19, but the effect of frailty has been unclear.METHODS: This multi-centre cohort study involved patients aged 18years and older hospitalised with COVID-19, using routinely collected data. We used Cox regression analysis to assess the impact of age, frailty, and delirium on the risk of inpatient mortality, adjusting for sex, illness severity, inflammation, and co-morbidities. We used ordinal logistic regression analysis to assess the impact of age, Clinical Frailty Scale (CFS), and delirium on risk of increased care requirements on discharge, adjusting for the same variables.RESULTS: Data from 5,711 patients from 55 hospitals in 12 countries were included (median age 74, IQR 54-83; 55.2% male). The risk of death increased independently with increasing age (&gt;80 vs 18-49: HR 3.57, CI 2.54-5.02), frailty (CFS 8 vs 1-3: HR 3.03, CI 2.29-4.00) inflammation, renal disease, cardiovascular disease, and cancer, but not delirium. Age, frailty (CFS 7 vs 1-3: OR 7.00, CI 5.27-9.32), delirium, dementia, and mental health diagnoses were all associated with increased risk of higher care needs on discharge. The likelihood of adverse outcomes increased across all grades of CFS from 4 to 9.CONCLUSIONS: Age and frailty are independently associated with adverse outcomes in COVID-19. Risk of increased care needs was also increased in survivors of COVID-19 with frailty or older age

Measurements of jet multiplicity and differential production cross sections of Z+jets events in proton-proton collisions at sqrt(s)=7TeV

Measurements of differential cross sections are presented for the production of a Z boson and at least one hadronic jet in proton-proton collisions at root s = 7 TeV, recorded by the CMS detector, using a data sample corresponding to an integrated luminosity of 4.9 fb(-1). The jet multiplicity distribution is measured for up to six jets. The differential cross sections are measured as a function of jet transverse momentum and pseudorapidity for the four highest transverse momentum jets. The distribution of the scalar sum of jet transverse momenta is also measured as a function of the jet multiplicity. The measurements are compared with theoretical predictions at leading and next-to-leading order in perturbative QCD.Austrian Federal Ministry of Science, Research and EconomyAustrian Science FundBelgian Fonds de la Recherche ScientifiqueFonds voor Wetenschappelijk OnderzoekConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ)Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Bulgarian Ministry of Education and ScienceCERNChinese Academy of SciencesMinistry of Science and TechnologyNational Natural ScienceFoundationofChinaColombian FundingAgency (COLCIENCIAS)Croatian Ministry of Science, Education, and SportCroatian Science FoundationResearch Promotion Foundation, CyprusMinistry of Education and Research, EstoniaEstonian Research Council, EstoniaEuropean Regional Development Fund, EstoniaAcademy of FinlandFinnish Ministry of Education and CultureHelsinki Institute of PhysicsInstitut National de Physique Nucleaire et de Physique des Particules / CNRS, FranceCommissariat a l&apos;Energie Atomique et aux Energies Alternatives / CEA, FranceBundesministerium fur Bildung und Forschung, GermanyDeutsche Forschungsgemeinschaft, GermanyHelmholtz-Gemeinschaft Deutscher Forschungs zentren, GermanyGeneral Secretariat for Research and Technology, GreeceNational Scientific Research Foundation, HungaryNational Innovation Office, HungaryDepartment of Atomic Energy, IndiaDepartment of Science and Technology, IndiaInstitute for Studies in Theoretical Physics and Mathematics, IranScience Foundation, IrelandIstituto Nazionale di Fisica Nucleare, ItalyKorean Ministry of Education, Science and Technology, Republic of KoreaWorld Class University program of NRF, Republic of KoreaLithuanian Academy of SciencesMinistry of Education, and University of Malaya (Malaysia)Mexican Funding Agency (CINVESTAV)Mexican Funding Agency (CONACYT)Mexican Funding Agency (SEP)Mexican Funding Agency (UASLP-FAI)Ministry of Business, Innovation and Employment, New ZealandPakistan Atomic Energy CommissionMinistry of Science and Higher Education, PolandNational Science Centre, PolandFundacao para a Cienciaea Tecnologia, PortugalJINR, DubnaMinistry of Education and Science of the Russian FederationFederal Agency of Atomic Energy of the Russian FederationRussian Academy of SciencesRussian Foundation for Basic ResearchMinistry of Education, Science and Technological Development of SerbiaSecretaria de Estado de Investigacion, Desarrollo e Innovacion and Programa Consolider-Ingenio, SpainSwiss Funding Agency (ETH Board)Swiss Funding Agency (ETH Zurich)Swiss Funding Agency (PSI)Swiss Funding Agency (SNF)Swiss Funding Agency (UniZH)Swiss Funding Agency (Canton Zurich)Swiss Funding Agency (SER)Ministry of Science and Technology, TaipeiThailand Center of Excellence in PhysicsInstitute for the Promotion of Teaching Science andTechnologyofThailandSpecialTaskForceforActivating ResearchNational Science and Technology Development Agency of ThailandScientific and Technical Research Council of TurkeyTurkish Atomic Energy AuthorityNational Academy of Sciences of Ukraine, UkraineState Fund for Fundamental Researches, UkraineScience and Technology Facilities Council, United KingdomU.S. Department of EnergyU.S. National Science FoundationMarie Curie programEuropean Research CouncilEPLANET (European Union)Leventis FoundationA. P. Sloan FoundationAlexander von Humboldt FoundationBelgian Federal Science Policy OfficeFonds pour la Formation a la Recherche dans l&apos;Industrie et dans l&apos;Agriculture (FRIA-Belgium)Agentschap voor Innovatie door Wetenschap en Technologie (IWT-Belgium)Ministry of Education, Youth and Sports (MEYS) of the Czech RepublicCouncil ofScienceandIndustrialResearch, IndiaHOMINGPLUS program of Foundation for Polish ScienceEuropean UnionRegional Development FundCompagnia di San Paolo (Torino)Consorzio per la Fisica (Trieste)MIUR (Italy)Thalis and Aristeia programsEU-ESFGreekNSRFNationalPrioritiesResearchProgram by Qatar National Research FundYerevan Phys Inst, Yerevan 375036, ArmeniaInst Hochenergiephys OeAW, Vienna, AustriaNatl Ctr Particle &High Energy Phys, Minsk, ByelarusUniv Antwerp, Antwerp, BelgiumVrije Univ Brussel, Brussels, BelgiumUniv Libre Bruxelles, Brussels, BelgiumUniv Ghent, B-9000 Ghent, BelgiumCatholic Univ Louvain, Louvain La Neuve, BelgiumUniv Mons, B-7000 Mons, BelgiumCtr Brasileiro Pesquisas Fis, Rio De Janeiro, BrazilUniv Estado Rio de Janeiro, BR-20550011 Rio De Janeiro, BrazilUniv Estadual Paulista, Sao Paulo, BrazilUniv Fed ABC, Sao Paulo, BrazilInst Nucl Energy Res, Sofia, BulgariaUniv Sofia, BU-1126 Sofia, BulgariaInst High Energy Phys, Beijing 100039, Peoples R ChinaPeking Univ, State Key Lab Nucl Phys &Technol, Beijing 100871, Peoples R ChinaUniv Los Andes, Bogota, ColombiaUniv Split, Fac Elect Engn, Mech Engn &Naval Architecture, Split, CroatiaUniv Split, Fac Sci, Split, CroatiaRudjer Boskovic Inst, Zagreb, CroatiaUniv Cyprus, CY-1678 Nicosia, CyprusCharles Univ Prague, Prague, Czech RepublicAcad Sci Res &Technol Arab Republ Egypt, Egyptian Network High Energy Phys, Cairo, EgyptNICPB, Tallinn, EstoniaUniv Helsinki, Dept Phys, Helsinki, FinlandHelsinki Inst Phys, Helsinki, FinlandLappeenranta Univ Technol, Lappeenranta, FinlandCEA Saclay, DSM IRFU, F-91191 Gif Sur Yvette, FranceEcole Polytech, IN2P3 CNRS, Lab Leprince Ringuet, Palaiseau, FranceUniv Strasbourg, Univ Haute Alsace Mulhouse, Inst Puridisciplinaire Hubert Curien, CNRS IN2P3, Strasbourg, FranceCtr Calcul Inst Natl Phys Nucl &Phys Particules, CNRS IN2P3, Villeurbanne, FranceUniv Lyon 1, Univ Lyon, Inst Phys Nucl Lyon, CNRS IN2P3, F-69622 Villeurbanne, FranceTbilisi State Univ, Inst High Energy Phys &Informatizat, GE-380086 Tbilisi, Rep of GeorgiaRWTH Aachen Univ I, Inst Phys, Aachen, GermanyRWTH Aachen Univ III, Phys Inst A, Aachen, GermanyRWTH Aachen Univ III, Phys Inst B, Aachen, GermanyDESY, Hamburg, GermanyUniv Hamburg, Hamburg, GermanyInst Expt Kernphys, Karlsruhe, GermanyNCSR Demokritos, Inst Nucl &Particle Phys, Aghia Paraskevi, GreeceUniv Athens, Athens, GreeceUniv Ioannina, GR-45110 Ioannina, GreeceWigner Res Ctr Phys, Budapest, HungaryInst Nucl Res ATOMKI, Debrecen, HungaryUniv Debrecen, Debrecen, HungaryNatl Inst Sci Educ &Res, Bhubaneswar, Orissa, IndiaPanjab Univ, Chandigarh 160014, IndiaUniv Delhi, Delhi 110007, IndiaSaha Inst Nucl Phys, Kolkata, IndiaBhabha Atom Res Ctr, Mumbai 400085, Maharashtra, IndiaTata Inst Fundamental Res, Mumbai 400005, Maharashtra, IndiaInst Res Fundamental Sci IPM, Tehran, IranUniv Coll Dublin, Dublin 2, IrelandIst Nazl Fis Nucl, Sez Bari, I-70126 Bari, ItalyUniv Bari, Bari, ItalyPolitecn Bari, Bari, ItalyIst Nazl Fis Nucl, Sez Bologna, I-40126 Bologna, ItalyUniv Bologna, Bologna, ItalyIst Nazl Fis Nucl, Sez Catania, I-95129 Catania, ItalyUniv Catania, Catania, ItalyCSFNSM, Catania, ItalyIst Nazl Fis Nucl, Sez Firenze, I-50125 Florence, ItalyUniv Florence, Florence, ItalyIst Nazl Fis Nucl, Lab Nazl Frascati, I-00044 Frascati, ItalyIst Nazl Fis Nucl, Sez Genova, I-16146 Genoa, ItalyUniv Genoa, Genoa, ItalyIst Nazl Fis Nucl, Sez Milano Bicocca, I-20133 Milan, ItalyUniv Milano Bicocca, Milan, ItalyIst Nazl Fis Nucl, Sez Napoli, I-80125 Naples, ItalyUniv Naples Federico II, Naples, ItalyUniv Basilicata Potenza, Naples, ItalyUniv G Marconi Roma, Naples, ItalyIst Nazl Fis Nucl, Sez Padova, Padua, ItalyUniv Padua, Padua, ItalyUniv Trento, Padua, ItalyIst Nazl Fis Nucl, Sez Pavia, I-27100 Pavia, ItalyUniv Pavia, I-27100 Pavia, ItalyIst Nazl Fis Nucl, Sez Perugia, I-06100 Perugia, ItalyUniv Perugia, I-06100 Perugia, ItalyIst Nazl Fis Nucl, Sez Pisa, Pisa, ItalyUniv Pisa, Pisa, ItalyScuola Normale Super Pisa, Pisa, ItalyIst Nazl Fis Nucl, Sez Roma, Rome, ItalyUniv Rome, Rome, ItalyIst Nazl Fis Nucl, Sez Torino, I-10125 Turin, ItalyUniv Turin, Turin, ItalyUniv Piemonte Orientale Novara, Turin, ItalyIst Nazl Fis Nucl, Sez Trieste, Trieste, ItalyUniv Trieste, Trieste, ItalyKangwon Natl Univ, Chunchon, South KoreaKyungpook Natl Univ, Daegu, South KoreaChonbuk Natl Univ, Jeonju 561756, South KoreaChonnam Natl Univ, Inst Univ &Elementary Particles, Kwangju, South KoreaKorea Univ, Seoul, South KoreaUniv Seoul, Seoul, South KoreaSungkyunkwan Univ, Suwon, South KoreaVilnius Univ, Vilnius, LithuaniaUniv Malaya, Natl Ctr Particle Phys, Kuala Lumpur, MalaysiaCtr Invest &Estudios Avanzados, IPN, Mexico City, DF, MexicoUniv Iberoamer, Mexico City, DF, MexicoBenemerita Univ Autonoma Puebla, Puebla, MexicoUniv Autonoma San Luis Potosi, San Luis Potosi, MexicoUniv Auckland, Auckland 1, New ZealandUniv Canterbury, Christchurch 1, New ZealandQuaid I Azam Univ, Natl Ctr Phys, Islamabad, PakistanNatl Ctr Nucl Res, Otwock, PolandUniv Warsaw, Fac Phys, Inst Expt Phys, Warsaw, PolandLab Instrumentacao &Fis Expt Particulas, Lisbon, PortugalJoint Inst Nucl Res, Dubna, RussiaPetersburg Nucl Phys Inst, St Petersburg, RussiaRussian Acad Sci, Inst Nucl Res, Moscow 117312, RussiaInst Theoret &Expt Phys, Moscow 117259, RussiaPN Lebedev Phys Inst, Moscow 117924, RussiaMoscow MV Lomonosov State Univ, Skobeltsyn Inst Nucl Phys, Moscow, RussiaInst High Energy Phys, State Res Ctr Russian Federat, Protvino, RussiaUniv Belgrade, Fac Phys, Belgrade 11001, SerbiaVinca Inst Nucl Sci, Belgrade, SerbiaCIEMAT, E-28040 Madrid, SpainUniv Autonoma Madrid, Madrid, SpainUniv Oviedo, Oviedo, SpainUniv Cantabria, CSIC, IFCA, E-39005 Santander, SpainCERN, European Org Nucl Res, CH-1211 Geneva, SwitzerlandPaul Scherrer Inst, Villigen, SwitzerlandETH, Inst Particle Phys, Zurich, SwitzerlandUniv Zurich, Zurich, SwitzerlandNatl Cent Univ, Chungli 32054, TaiwanNatl Taiwan Univ, Taipei 10764, TaiwanChulalongkorn Univ, Fac Sci, Dept Phys, Bangkok, ThailandCukurova Univ, Adana, TurkeyMiddle E Tech Univ, Dept Phys, TR-06531 Ankara, TurkeyBogazici Univ, Istanbul, TurkeyIstanbul Tech Univ, TR-80626 Istanbul, TurkeyKharkov Phys &Technol Inst, Natl Sci Ctr, UA-310108 Kharkov, UkraineUniv Bristol, Bristol, Avon, EnglandRutherford Appleton Lab, Didcot OX11 0QX, Oxon, EnglandUniv London Imperial Coll Sci Technol &Med, London, EnglandBrunel Univ, Uxbridge UB8 3PH, Middx, EnglandBaylor Univ, Waco, TX 76798 USAUniv Alabama, Tuscaloosa, AL USABoston Univ, Boston, MA 02215 USABrown Univ, Providence, RI 02912 USAUniv Calif Davis, Davis, CA 95616 USAUniv Calif Los Angeles, Los Angeles, CA USAUniv Calif Riverside, Riverside, CA 92521 USAUniv Calif San Diego, La Jolla, CA 92093 USAUniv Calif Santa Barbara, Santa Barbara, CA 93106 USACALTECH, Pasadena, CA 91125 USACarnegie Mellon Univ, Pittsburgh, PA 15213 USAUniv Colorado, Boulder, CO 80309 USACornell Univ, Ithaca, NY USAFairfield Univ, Fairfield, CT 06430 USAFermilab Natl Accelerator Lab, Batavia, IL 60510 USAUniv Florida, Gainesville, FL USAFlorida Int Univ, Miami, FL 33199 USAFlorida State Univ, Tallahassee, FL 32306 USAFlorida Inst Technol, Melbourne, FL 32901 USAUniv Illinois, Chicago, IL USAUniv Iowa, Iowa City, IA USAJohns Hopkins Univ, Baltimore, MD USAUniv Kansas, Lawrence, KS 66045 USAKansas State Univ, Manhattan, KS 66506 USALawrence Livermore Natl Lab, Livermore, CA USAUniv Maryland, College Pk, MD 20742 USAMIT, Cambridge, MA 02139 USAUniv Minnesota, Minneapolis, MN USAUniv Mississippi, Oxford, MS USAUniv Nebraska, Lincoln, NE USASUNY Buffalo, Buffalo, NY 14260 USANortheastern Univ, Boston, MA 02115 USANorthwestern Univ, Evanston, IL USAUniv Notre Dame, Notre Dame, IN 46556 USAOhio State Univ, Columbus, OH 43210 USAPrinceton Univ, Princeton, NJ 08544 USAUniv Puerto Rico, Mayaguez, PR USAPurdue Univ, W Lafayette, IN 47907 USAPurdue Univ Calumet, Hammond, LA USARice Univ, Houston, TX USAUniv Rochester, Rochester, NY 14627 USARockefeller Univ, New York, NY 10021 USARutgers State Univ, Piscataway, NJ USAUniv Tennessee, Knoxville, TN USATexas A&amp;M Univ, College Stn, TX USATexas Tech Univ, Lubbock, TX 79409 USAVanderbilt Univ, Nashville, TN 37235 USAUniv Virginia, Charlottesville, VA USAWayne State Univ, Detroit, MI USAUniv Wisconsin, Madison, WI 53706 USAVienna Univ Technol, A-1040 Vienna, AustriaUniv Haute Alsace Mulhouse, Univ Strasbourg, Inst Pluridisciplinaire Hubert Curien, CNRS IN2P3, Strasbourg, FranceUniv Estadual Campinas, Campinas, SP, BrazilSuez Univ, Suez, EgyptCairo Univ, Cairo, EgyptFayoum Univ, Al Fayyum, EgyptBritish Univ Egypt, Cairo, EgyptAin Shams Univ, Cairo, EgyptUniv Haute Alsace, Mulhouse, FranceBrandenburg Tech Univ Cottbus, Cottbus, GermanyInst Nucl Res, ATOMKI, H-4001 Debrecen, HungaryEotvos Lorand Univ, Budapest, HungaryVisva Bharati Univ, Santini Ketan, W Bengal, IndiaKing Abdulaziz Univ, Jeddah 21413, Saudi ArabiaUniv Ruhuna, Matara, Sri LankaIsfahan Univ Technol, Esfahan, IranSharif Univ Technol, Tehran, IranIslamic Azad Univ, Plasma Phys Res Ctr, Sci &Res Branch, Tehran, IranIst Nazl Fis Nucl, Lab Nazl Legnaro, I-35020 Legnaro, ItalyUniv Siena, I-53100 Siena, ItalyCNRS, IN2P3, Paris, FranceUniv Michoacana, Morelia, Michoacan, MexicoSt Petersburg State Polytech Univ, St Petersburg, RussiaUniv Rome, Fac Ingn, Rome, ItalyIst Nazl Fis Nucl, Scuola Normale &Sez, Pisa, ItalyAlbert Einstein Ctr Fundamental Phys, Bern, SwitzerlandGaziosmanpasa Univ, Tokat, TurkeyAdiyaman Univ, Adiyaman, TurkeyCag Univ, Mersin, TurkeyMersin Univ, Mersin, TurkeyIzmir Inst Technol, Izmir, TurkeyOzyegin Univ, Istanbul, TurkeyMarmara Univ, Istanbul, TurkeyKafkas Univ, Kars, TurkeyMimar Sinan Univ, Istanbul, TurkeyUniv Southampton, Sch Phys &Astron, Southampton, Hants, EnglandArgonne Natl Lab, Argonne, IL 60439 USAErzincan Univ, Erzincan, TurkeyYildiz Tekn Univ, Istanbul, TurkeyTexas A&amp;M Univ, Doha, QatarUniv Estadual Paulista, Instituto de Física Teórica (IFT), Sao Paulo, BrazilEstonian Research Council, Estonia: IUT23-4Estonian Research Council, Estonia: IUT23-6MIUR (Italy): 20108T4XT